BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
13 12 2022
Historique:
received: 16 05 2022
accepted: 28 11 2022
entrez: 13 12 2022
pubmed: 14 12 2022
medline: 16 12 2022
Statut: epublish

Résumé

Several studies have shown that SARS-CoV-2 BA.1 omicron is an immune escape variant. Meanwhile, however, omicron BA.2 and BA.5 became dominant in many countries and replaced BA.1. As both have several mutations compared to BA.1, we analyzed whether BA.2 and BA.5 show further immune escape relative to BA.1. Here, we characterized neutralization profiles against the BA.2 and BA.5 omicron sub-variants in plasma samples from individuals with different history of exposures to infection/vaccination and found that unvaccinated individuals after a single exposure to BA.2 had limited cross-neutralizing antibodies to pre-omicron variants and to BA.1. Consequently, our antigenic map including all Variants of Concern and BA.1, BA.2 and BA.5 omicron sub-variants, showed that all omicron sub-variants are distinct to pre-omicron variants, but that the three omicron variants are also antigenically distinct from each other. The antibody landscapes illustrate that cross-neutralizing antibodies against the current antigenic space, as described in our maps, are generated only after three or more exposures to antigenically close variants but also after two exposures to antigenically distant variants. Here, we describe the antigenic space inhabited by the relevant SARS-CoV-2 variants, the understanding of which will have important implications for further vaccine strain adaptations.

Identifiants

pubmed: 36513653
doi: 10.1038/s41467-022-35312-3
pii: 10.1038/s41467-022-35312-3
pmc: PMC9745279
doi:

Substances chimiques

Broadly Neutralizing Antibodies 0
Antibodies, Viral 0
Antibodies, Neutralizing 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

7701

Subventions

Organisme : NIAID NIH HHS
ID : 75N93021C00014
Pays : United States

Informations de copyright

© 2022. The Author(s).

Références

Commun Med (Lond). 2021;1(1):4
pubmed: 34870284
Nat Med. 2022 Jun;28(6):1297-1302
pubmed: 35322239
Cell. 2022 Jul 7;185(14):2422-2433.e13
pubmed: 35772405
Cell Host Microbe. 2022 Feb 9;30(2):154-162.e5
pubmed: 35120605
Science. 2022 Aug 19;377(6608):890-894
pubmed: 35857529
Science. 2004 Jul 16;305(5682):371-6
pubmed: 15218094
Immunity. 2021 Dec 14;54(12):2893-2907.e5
pubmed: 34614412
Science. 2014 Nov 21;346(6212):996-1000
pubmed: 25414313
Viruses. 2021 Dec 11;13(12):
pubmed: 34960755
Science. 2021 Dec 10;374(6573):1343-1353
pubmed: 34672695
Immunity. 2022 Sep 13;55(9):1725-1731.e4
pubmed: 35973428
Sci Immunol. 2021 Apr 15;6(58):
pubmed: 33858945
Cell Rep. 2021 Aug 24;36(8):109570
pubmed: 34390647
N Engl J Med. 2022 May 5;386(18):1764-1766
pubmed: 35320661
Front Immunol. 2022 Mar 24;13:861050
pubmed: 35401572
Nature. 2022 Jul;607(7918):356-359
pubmed: 35523247
Nature. 2022 Feb;602(7898):664-670
pubmed: 35016195
Nat Commun. 2022 Jul 4;13(1):3840
pubmed: 35787633
Nature. 2022 Feb;602(7898):654-656
pubmed: 35016196
Nature. 2022 Feb;602(7898):682-688
pubmed: 35016197
Nat Med. 2022 Mar;28(3):496-503
pubmed: 35090165
Sci Immunol. 2022 Mar 25;7(69):eabo2202
pubmed: 35113647
Nature. 2022 Apr;604(7906):553-556
pubmed: 35240676
Nat Med. 2021 Jun;27(6):981-984
pubmed: 33795870
Viruses. 2022 Jun 18;14(6):
pubmed: 35746806
Cell Host Microbe. 2022 Dec 14;30(12):1745-1758.e7
pubmed: 36356586
Cell. 2022 Mar 3;185(5):847-859.e11
pubmed: 35139340
N Engl J Med. 2022 Feb 17;386(7):698-700
pubmed: 35021005
N Engl J Med. 2022 Apr 21;386(16):1579-1580
pubmed: 35294809
Vaccines (Basel). 2020 Dec 28;9(1):
pubmed: 33379160
Nature. 2022 Mar;603(7901):488-492
pubmed: 35102311
N Engl J Med. 2022 Oct 6;387(14):1279-1291
pubmed: 36112399
JCI Insight. 2022 Oct 10;7(19):
pubmed: 36214224
Cell Host Microbe. 2022 Jan 12;30(1):53-68.e12
pubmed: 34921776
Sci Immunol. 2022 Sep 23;7(75):eabq4450
pubmed: 35737747

Auteurs

Annika Rössler (A)

Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Peter-Mayr-Str. 4b, 6020, Innsbruck, Austria.

Antonia Netzl (A)

University of Cambridge, Center for Pathogen Evolution, Department of Zoology, Cambridge, UK.

Ludwig Knabl (L)

Tyrolpath Obrist Brunhuber GmbH, Hauptplatz 4, 6511, Zams, Austria.

Helena Schäfer (H)

Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Peter-Mayr-Str. 4b, 6020, Innsbruck, Austria.

Samuel H Wilks (SH)

University of Cambridge, Center for Pathogen Evolution, Department of Zoology, Cambridge, UK.

David Bante (D)

Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Peter-Mayr-Str. 4b, 6020, Innsbruck, Austria.

Barbara Falkensammer (B)

Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Peter-Mayr-Str. 4b, 6020, Innsbruck, Austria.

Wegene Borena (W)

Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Peter-Mayr-Str. 4b, 6020, Innsbruck, Austria.

Dorothee von Laer (D)

Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Peter-Mayr-Str. 4b, 6020, Innsbruck, Austria.

Derek J Smith (DJ)

University of Cambridge, Center for Pathogen Evolution, Department of Zoology, Cambridge, UK. djs200@cam.ac.uk.

Janine Kimpel (J)

Institute of Virology, Department of Hygiene, Microbiology and Public Health, Medical University of Innsbruck, Peter-Mayr-Str. 4b, 6020, Innsbruck, Austria. Janine.Kimpel@i-med.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH